ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

ANAB AnaptysBio Inc

26,58
0,24 (0,91%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
AnaptysBio Inc ANAB NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,24 0,91% 26,58 22:33:53
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
26,76 25,64 27,02 26,58 26,34
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
24.4.202415:00PRNUSActym Therapeutics Appoints Thomas Smart as CEO
11.3.202421:41EDGAR2Form S-8 - Securities to be offered to employees in employee..
11.3.202421:36EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11.3.202421:19EDGAR2Form 8-K - Current report
29.2.202415:15GLOBEAnaptys to Present at TD Cowen’s 44th Annual Health Care..
14.2.202416:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202414:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31.1.202415:15GLOBEAnaptys to Present at Guggenheim’s 6th Annual Biotechnology..
10.1.202401:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.1.202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202422:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202422:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202422:09EDGAR2Form 8-K - Current report
27.11.202322:17EDGAR2Form 8-K - Current report
27.11.202322:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
07.11.202322:15GLOBEAnaptys Named a BioSpace 2024 Best Places to Work Winner
02.11.202321:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02.11.202321:18EDGAR2Form 8-K - Current report
02.11.202321:15GLOBEAnaptys Announces Third Quarter 2023 Financial Results and..
01.11.202314:15GLOBEAnaptys Announces Participation in November Investor..
25.10.202322:43EDGAR2Form 8-K - Current report
11.10.202315:15GLOBEAnaptys to Present Phase 1 Data on ANB032, its BTLA Agonist..
10.10.202315:01EDGAR2Form 8-K - Current report
09.10.202314:43DJNAnaptys Sees Positive Trial Results for Imsidolimad..
09.10.202314:15GLOBEAnaptys to Provide Overview of Rosnilimab, a PD-1 Agonist,..
09.10.202314:00GLOBEAnaptys Announces Positive Top-Line Phase 3 Clinical Trial..
19.9.202300:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.9.202300:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.9.202300:09EDGAR2Form 3 - Initial statement of beneficial ownership of..
18.9.202322:18EDGAR2Form 8-K - Current report
18.9.202322:15GLOBEAnaptysBio Announces Appointment of John Orwin as Chairman..
12.9.202315:15GLOBEAnaptysBio to Present at the Stifel 2023 Immunology and..
07.8.202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.8.202322:18EDGAR2Form 8-K - Current report
07.8.202322:15GLOBEAnaptysBio Announces Second Quarter 2023 Financial..
31.7.202320:27DJNAnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy..
31.7.202319:34GLOBEAnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI..
30.5.202322:15GLOBEAnaptysBio Announces Participation in Upcoming Investor..
11.5.202322:15GLOBEAnaptysBio Announces First Quarter 2023 Financial Results..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock